Edgestream Partners L.P. bought a new position in shares of QuidelOrtho Corporation (NASDAQ:QDEL – Free Report) in the third quarter, Holdings Channel reports. The institutional investor bought 454,053 shares of the company’s stock, valued at approximately $4,786,000.
A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in QDEL. GAMMA Investing LLC grew its stake in QuidelOrtho by 67.7% during the second quarter. GAMMA Investing LLC now owns 2,185 shares of the company’s stock worth $38,000 after buying an additional 882 shares during the last quarter. IFP Advisors Inc boosted its holdings in shares of QuidelOrtho by 14,166.7% in the 2nd quarter. IFP Advisors Inc now owns 2,568 shares of the company’s stock worth $45,000 after acquiring an additional 2,550 shares in the last quarter. Integrated Wealth Concepts LLC bought a new stake in QuidelOrtho during the 2nd quarter worth approximately $53,000. Allworth Financial LP bought a new stake in QuidelOrtho during the 2nd quarter worth approximately $56,000. Finally, Net Worth Advisory Group acquired a new stake in QuidelOrtho during the 3rd quarter valued at $113,000. 99.00% of the stock is currently owned by institutional investors and hedge funds.
Analyst Ratings Changes
Several analysts have recently commented on the company. Zacks Research upgraded QuidelOrtho from a “strong sell” rating to a “hold” rating in a report on Friday, October 9th. Weiss Ratings reiterated a “sell (e+)” rating on shares of QuidelOrtho in a research report on Thursday, October 15th. Four equities research analysts have rated the stock with a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Reduce” and a consensus target price of $13.62.
Read Our Latest Research Report on QuidelOrtho
QuidelOrtho Price Performance
Shares of QDEL stock opened at $8.92 on Friday. The firm has a market cap of $612.00 million, a price-to-earnings ratio of 11.13 and a beta of 0.77. QuidelOrtho Corporation has a 12 month low of $8.88 and a 12 month high of $35.58. The company has a quick ratio of 0.75, a current ratio of 1.36 and a debt-to-equity ratio of 1.40. The stock has a 50-day moving average price of $12.04 and a 200 day moving average price of $15.17.
QuidelOrtho (NASDAQ:QDEL – Get Free Report) last issued its quarterly earnings results on Tuesday, November 3rd. The company reported $0.31 EPS for the quarter, topping the consensus estimate of $0.18 by $0.13. QuidelOrtho had a negative net margin of 14.24% and a positive return on equity of 3.22%. The company had revenue of $618.90 million during the quarter, compared to analysts’ expectations of $627.83 million. During the same quarter in the previous year, the company earned $0.80 EPS. QuidelOrtho’s revenue was down 11.6% on a year-over-year basis. Research analysts expect that QuidelOrtho Corporation will post 0.66 EPS for the current year.
About QuidelOrtho
QuidelOrtho Corporation develops and manufactures diagnostic testing products used in healthcare settings. Its offerings include tests and instruments for immunoassay, molecular diagnostics, clinical chemistry, and transfusion medicine, as well as rapid tests designed for point-of-care use. The company serves hospitals, clinical laboratories, blood banks, physician offices, and other healthcare providers. Its product lines include the VITROS clinical laboratory systems, ORTHO VISION blood-bank analyzers, and Sofia rapid diagnostic platforms.
See Also
- Five stocks we like better than QuidelOrtho
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Want to see what other hedge funds are holding QDEL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for QuidelOrtho Corporation (NASDAQ:QDEL – Free Report).
Receive News & Ratings for QuidelOrtho Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for QuidelOrtho and related companies with MarketBeat.com's FREE daily email newsletter.
